The additive value of morphologic grouping in assessing treatment response to ablative radiation therapy in liver metastases
Maria El Homsi(Memorial Sloan Kettering Cancer Center), Carla Hajj(Memorial Sloan Kettering Cancer Center), Firas S. Ahmed(Memorial Sloan Kettering Cancer Center), Neal Kim(Memorial Sloan Kettering Cancer Center), Christopher H. Crane(Memorial Sloan Kettering Cancer Center), Dina Hamdan(Icahn School of Medicine at Mount Sinai), Jared Bassmann(Memorial Sloan Kettering Cancer Center), Marsha Reyngold(Memorial Sloan Kettering Cancer Center), Natally Horvat(Alliance Data (United States))
Cited by 0
Related Papers
Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma
|Journal of Clinical Oncology|2015|474
Phase II Trial of Preoperative Chemoradiation in Patients With Localized Gastric Adenocarcinoma (RTOG 9904): Quality of Combined Modality Therapy and Pathologic Response
|Journal of Clinical Oncology|2006|385
Metastatic Pancreatic Cancer: ASCO Guideline Update
|Journal of Clinical Oncology|2020|287
Protons versus Photons for Unresectable Hepatocellular Carcinoma: Liver Decompensation and Overall Survival
|International Journal of Radiation Oncology*Biology*Physics|2019|147